i2o Therapeutics: i2O Therapeutics Receives Strategic Investment from Colorcon Ventures and Enters into Research Collaboration with Colorcon
i2O Therapeutics, an innovative biotech company developing a platform to enable oral delivery of traditionally injectable biological drugs, has received a strategic investment from Colorcon Ventures, the corporate venture fund of Colorcon Inc.
Read full article »
i2o is a Massachusetts-based biotechnology company that researches and develops oral peptide and protein therapies for the treatment of cardiometabolic diseases.
Read more